NCDEH6DMn7
liked
$Gorilla Technology (GRRR.US)$ it's all about the earning, but I do support anyone that has the share to continue hodl 🦍🦍🦍


3
NCDEH6DMn7
liked
NCDEH6DMn7
liked
$S&P 500 Index (.SPX.US)$
$E-mini S&P 500 Futures(JUN5) (ESmain.US)$
Hereby, I declare the start of Bear 🐻 Market, the return of 2022.
Although no one can predict the future well, I still declare it anyway but this is your responsibility if you take my comments.
If you want to attack me and leave hurtful comments, please show me your portfolio, transaction history, and performance report, and we will talk on the same level. If you cannot disclose anything, leave...
$E-mini S&P 500 Futures(JUN5) (ESmain.US)$
Hereby, I declare the start of Bear 🐻 Market, the return of 2022.
Although no one can predict the future well, I still declare it anyway but this is your responsibility if you take my comments.
If you want to attack me and leave hurtful comments, please show me your portfolio, transaction history, and performance report, and we will talk on the same level. If you cannot disclose anything, leave...

17
8
NCDEH6DMn7
liked
Bought a call Options, it is about to expire, what will happen if it is not sold?
Translated

7
4
NCDEH6DMn7
liked
$DocuSign (DOCU.US)$ is expected to report its quarterly fiscal Q4 2025 earnings result on 13 March 2025 after market close.
The latest consensus estimate for revenue is anticipated to come in at $759.96 million, up 6.68% from the same period last year. The earnings per share consensus estimate is expected to come in at 85 cents which represent a 10.53% increase from same period last year.
DocuSign (DOCU) Last Positive Earnin...
The latest consensus estimate for revenue is anticipated to come in at $759.96 million, up 6.68% from the same period last year. The earnings per share consensus estimate is expected to come in at 85 cents which represent a 10.53% increase from same period last year.
DocuSign (DOCU) Last Positive Earnin...



+1
8
1
NCDEH6DMn7
liked
$Xilio Therapeutics (XLO.US)$
Xilio's Q4/FY2024 report delivers multiple positive catalysts that strengthen the company's position. The AbbVie collaboration announced in Q1 2025 is transformative, providing $52 million in upfront payments ($10 million via equity investment) and potential milestone payments up to $2.1 billion plus royalties. This deal effectively doubles the company's cash position and provides important validation for Xilio's tumor-activation platform.
...
Xilio's Q4/FY2024 report delivers multiple positive catalysts that strengthen the company's position. The AbbVie collaboration announced in Q1 2025 is transformative, providing $52 million in upfront payments ($10 million via equity investment) and potential milestone payments up to $2.1 billion plus royalties. This deal effectively doubles the company's cash position and provides important validation for Xilio's tumor-activation platform.
...
5